Lisata Therapeutics, Inc. ( (LSTA) ) has released its Q3 earnings. Here is a breakdown of the information Lisata Therapeutics, Inc. presented to its investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases, utilizing its proprietary cyclic peptide product candidate, certepetide. In its third quarter of 2025, Lisata reported positive clinical trial data for certepetide, strategic alliances with Catalent and GATC Health, and a financial position that extends its cash runway into early 2027. Key highlights include a decrease in operating expenses by 17.3% compared to the previous year, with research and development costs reduced by 22.9%. The company also announced a global license agreement with Catalent and a strategic alliance with GATC Health, enhancing its drug discovery capabilities. Looking ahead, Lisata anticipates continued data flow from its clinical trials and maintains a positive outlook on its financial and strategic positioning, expecting to fund operations into the first quarter of 2027.